Pharmaceutical The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness watchdog for England and Wales, has recommended Translarna (ataluren), from US pharma company PTC Therapeutics, for children with Duchenne muscular dystrophy (DMD) caused by a nonsense mutation, after reaching a ‘managed access agreement’. 20 July 2016